崔喜喜 江珊

【摘要】 目的：探討红花注射液对冠心病患者血流动力学、心肌酶谱及IGF-Ⅰ水平的影响。方法：选取2018年5月-2020年6月本院收治的96例冠心病（CHD）患者，按照随机数字法将其分为基础组和中药组，每组48例。基础组采用常规药物干预，中药组在基础组的基础上加用红花注射液。比较两组不良反应发生情况及治疗前后的血流动力学（Hct、np、FIB、ESR）、心肌酶谱（cTnI、CPK、CK-MB、Mb）、血清IGF-Ⅰ、TGF-β1水平及血脂代谢指标（TC、TG、LDL-C、HDL-C）。结果：治疗前，两组Hct、np、FIB、ESR、cTnI、CPK、CK-MB、Mb比较，差异均无统计学意义（P>0.05）;治疗后，两组Hct、np、FIB、ESR、cTnI、CPK、CK-MB、Mb均低于治疗前，且中药组均低于基础组，差异均有统计学意义（P<0.05）。治疗前，两组IGF-Ⅰ、TGF-β1比较，差异均无统计学意义（P>0.05）;治疗后，两组IGF-Ⅰ、TGF-β1均高于治疗前，且中药组均高于基础组，差异均有统计学意义（P<0.05）。治疗前，两组患者TC、TG、LDL-C、HDL-C比较，差异均无统计学意义（P>0.05）;治疗后，两组HDL-C高于治疗前，TC、TG、LDL-C均低于治疗前，中药组HDL-C高于基础组，TC、TG、LDL-C均低于基础组，差异均有统计学意义（P<0.05）。中药组不良反应发生率为25.0%低于基础组的50.0%，差异有统计学意义（P<0.05）。结论：红花注射液可改善冠心病患者血流动力学，调节心肌酶谱水平，增加IGF-Ⅰ、TGF-β1表达，改善血脂代谢指标，安全性较高。

【关键词】 冠心病 红花注射液 IGF-Ⅰ TGF-β1 血流动力学 心肌酶谱

Effects of Honghua Injection on Hemodynamics， Myocardial Enzyme Spectrum and IGF-Ⅰ Level in Patients with Coronary Heart Disease/CUI Xixi， JIANG Shan. //Medical Innovation of China， 2021， 18（28）： 0-020

[Abstract] Objective： To investigate the effect of Honghua Injection on hemodynamic， myocardial enzyme spectrum and IGF-Ⅰ level in patients with coronary heart disease. Method： A total of 96 patients with coronary heart disease （CHD） admitted to our hospital from May 2018 to June 2020 were selected， and they were divided into basic group and traditional Chinese medicine group according to random number method， 48 cases in each group. The basic group was treated with conventional drug intervention， and the traditional Chinese medicine group was treated with Honghua Injection on the basis of the basic group. The incidence of adverse reactions was compared between two groups， hemodynamics （Hct， np， FIB， ESR）， myocardial enzyme spectrum （cTnI， CPK， CK-MB， Mb）， serum IGF-Ⅰ， TGF-β1 levels and lipid metabolism indexes （TC， TG， LDL-C， HDL-C） before and after treatment were compared between two groups. Result： Before treatment， there were no significant differences in Hct， np， FIB， ESR， cTnI， CPK， CK-MB and Mb between two groups （P>0.05）; after treatment， Hct， np， FIB， ESR， cTnI， CPK， CK-MB and Mb in both groups were lower than those before treatment， and those in the traditional Chinese medicine group were lower than those in the basic group， the differences were statistically significant （P<0.05）. Before treatment， there were no significant differences in IGF-Ⅰ and TGF-β1 between two groups （P>0.05）; after treatment， IGF-Ⅰ and TGF-β1 in both groups were higher than those before treatment， and those in the traditional Chinese medicine group were higher than those in the basic group， the differences were statistically significant （P<0.05）. Before treatment， there were no significant differences in TC， TG， LDL-C and HDL-C between two groups （P>0.05）; after treatment， HDL-C in both groups were higher than those before treatment， TC， TG and LDL-C in both groups were lower than those before treatment， HDL-C in the traditional Chinese medicine group was higher than that in the basic group， TC， TG and LDL-C in the traditional Chinese medicine group were lower than those in the basic group， the differences were statistically significant （P<0.05）. The incidence of adverse reaction in the traditional Chinese medicine group was 25.0%， which was lower than 50.0% in the basic group， the difference was statistically significant （P<0.05）. Conclusion： Honghua Injection improves hemodynamics in patients with coronary heart disease， regulates the level of myocardial enzyme spectrum， and increases IGF-Ⅰ and TGF-β1 expression， improve blood lipid metabolism index， and high safety.

[Key words] Coronary heart disease Honghua Injection IGF-Ⅰ TGF-β1 Hemodynamics Myocardial enzyme spectrum

First-author’s address： Graduate School of Jinzhou Medical University， Jinzhou 121000， China

doi：10.3969/j.issn.1674-4985.2021.28.004

冠心病（CHD）是机体冠脉出现斑块堵塞，动脉狭窄导致心肌缺血、坏死的一种心血管疾病。流行病调查显示：CHD在美国及发达国家死亡率排列第一，随着人口老龄化的加剧，我国CHD发病率升高，是心血管疾病死亡的主要原因[1]。CHD典型症状为胸痛、胸闷劳累时加剧，可累及肩部疼痛，休息及药物干预后可缓解[2]。……